glp-1 agonists muscle loss Explained GLP-1 Agonists For Obesity In

Dena M, Svensson AM, Olofsson KE et al (2021) Renal complications and duration of diabetes: an international comparison in persons with type 1 diabetes

Asian adults have the lowest obesity rates in the U.S

7 Similarly, a joint guideline by the American Diabetes Association (ADA) and European Association for the Study of Diabetes (EASD) recommends GLP-1RAs as second- or third-line therapy in patients with predominantly atherosclerotic cardiovascular disease, a compelling need to minimise hypoglycaemia or a need to promote weight loss

12,13 As evidence of our concern about patients taking GLP-1 receptor agonists, we identified a recent case report that described a patient taking semaglutide who experienced an aspiration event with food remains during induction of anesthesia despite having fasted for 18 hours

Abstract Glucagon-like peptide 1 receptor agonists (GLP-1RAs) are increasingly being used to treat diabetes and obesity